Lucid Diagnostics

LUCDNASDAQ
$0.860000
-0.02-2.29%
Pre-Market: 6:07 PM EDT
15 minutes delayed
Lucid Diagnostics (LUCD) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$12.00
Lowest Price Target1
$2.50
Consensus Price Target1
$5.42

want to know what
the Bulls & Bears Say?

Lucid Diagnostics (NASDAQ:LUCD) Stock, Analyst Ratings, Price Targets, Forecasts

Lucid Diagnostics Inc has a consensus price target of $5.42 based on the ratings of 6 analysts. The high is $12 issued by Canaccord Genuity on March 29, 2022. The low is $2.5 issued by Needham on May 13, 2024. The 3 most-recent analyst ratings were released by Ascendiant Capital, Cantor Fitzgerald, and Needham on June 6, 2024, May 15, 2024, and May 13, 2024, respectively. With an average price target of $4.33 between Ascendiant Capital, Cantor Fitzgerald, and Needham, there's an implied 403.88% upside for Lucid Diagnostics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Mar
0
0
0
0
Apr
1
May
0
0
0
0
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Ascendiant Capital
Cantor Fitzgerald
Needham
Cantor Fitzgerald
BTIG

1calculated from analyst ratings

Analyst Ratings for Lucid Diagnostics

Buy NowGet Alert
06/06/2024Buy Now772.09%Ascendiant Capital
Edward Woo
$8 → $7.5MaintainsBuyGet Alert
05/15/2024Buy Now248.84%Cantor Fitzgerald
Ross Osborn
 → $3ReiteratesOverweight → OverweightGet Alert
05/13/2024Buy Now190.7%Needham
Mike Matson
 → $2.5ReiteratesBuy → BuyGet Alert
04/12/2024Buy Now190.7%Needham
Mike Matson
 → $2.5ReiteratesBuy → BuyGet Alert
03/27/2024Buy Now190.7%Needham
Mike Matson
 → $2.5ReiteratesBuy → BuyGet Alert
03/27/2024Buy Now248.84%Cantor Fitzgerald
Ross Osborn
$3.8 → $3MaintainsOverweightGet Alert
11/14/2023Buy Now190.7%Needham
Mike Matson
$2.8 → $2.5MaintainsBuyGet Alert
09/26/2023Buy Now365.12%Cantor Fitzgerald
Ross Osborn
 → $4ReiteratesOverweight → OverweightGet Alert
08/22/2023Buy Now365.12%Cantor Fitzgerald
Charles Duncan
 → $4ReiteratesOverweight → OverweightGet Alert
08/16/2023Buy Now365.12%Cantor Fitzgerald
Charles Duncan
 → $4ReiteratesOverweight → OverweightGet Alert
08/16/2023Buy Now225.58%Needham
Mike Matson
 → $2.8ReiteratesBuy → BuyGet Alert
05/17/2023Buy Now365.12%Cantor Fitzgerald
Charles Duncan
$4.5 → $4MaintainsOverweightGet Alert
05/17/2023Buy Now225.58%Needham
Mike Matson
$2.6 → $2.8MaintainsBuyGet Alert
04/21/2023Buy Now202.33%Needham
Mike Matson
 → $2.6Reiterates → BuyGet Alert
03/14/2023Buy Now202.33%Needham
Mike Matson
$3.1 → $2.6MaintainsBuyGet Alert
11/18/2022Buy Now306.98%BTIG
Mark Massaro
$5 → $3.5MaintainsBuyGet Alert
11/15/2022Buy Now260.47%Needham
Mike Matson
$4.25 → $3.1MaintainsBuyGet Alert
08/16/2022Buy Now394.19%Needham
Mike Matson
$5 → $4.25MaintainsBuyGet Alert
05/12/2022Buy Now481.4%Needham
Mike Matson
$7 → $5MaintainsBuyGet Alert
03/29/2022Buy Now1295.35%Canaccord Genuity
Kyle Mikson
$18 → $12MaintainsBuyGet Alert
03/29/2022Buy Now713.95%Needham
Mike Matson
$13 → $7MaintainsBuyGet Alert
12/27/2021Buy Now1760.47%Ascendiant Capital
Edward Woo
 → $16Initiates → BuyGet Alert
12/15/2021Buy Now1411.63%Needham
Mike Matson
—MaintainsBuyGet Alert
11/08/2021Buy Now1527.91%BTIG
Mark Massaro
—Initiates → BuyGet Alert
11/08/2021Buy Now1993.02%Canaccord Genuity
Kyle Mikson
—Initiates → BuyGet Alert
11/08/2021Buy Now2341.86%Cantor Fitzgerald
Charles Duncan
—Initiates → OverweightGet Alert
11/08/2021Buy Now1876.74%Needham
Mike Matson
—Initiates → BuyGet Alert

FAQ

Q

What is the target price for Lucid Diagnostics (LUCD) stock?

A

The latest price target for Lucid Diagnostics (NASDAQ:LUCD) was reported by Ascendiant Capital on June 6, 2024. The analyst firm set a price target for $7.50 expecting LUCD to rise to within 12 months (a possible 772.09% upside). 11 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Lucid Diagnostics (LUCD)?

A

The latest analyst rating for Lucid Diagnostics (NASDAQ:LUCD) was provided by Ascendiant Capital, and Lucid Diagnostics maintained their buy rating.

Q

When was the last upgrade for Lucid Diagnostics (LUCD)?

A

There is no last upgrade for Lucid Diagnostics

Q

When was the last downgrade for Lucid Diagnostics (LUCD)?

A

There is no last downgrade for Lucid Diagnostics.

Q

When is the next analyst rating going to be posted or updated for Lucid Diagnostics (LUCD)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lucid Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lucid Diagnostics was filed on June 6, 2024 so you should expect the next rating to be made available sometime around June 6, 2025.

Q

Is the Analyst Rating Lucid Diagnostics (LUCD) correct?

A

While ratings are subjective and will change, the latest Lucid Diagnostics (LUCD) rating was a maintained with a price target of $8.00 to $7.50. The current price Lucid Diagnostics (LUCD) is trading at is $0.86, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch